Drug Profile


Alternative Names: Arestvyr; SIGA-246; ST-246®; TPOXX

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator ViroPharma
  • Developer Biomedical Advanced Research and Development Authority; SIGA Technologies
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Orthopoxvirus infections
  • Preclinical Smallpox

Most Recent Events

  • 29 Aug 2016 Adverse events data from a phase III trial in Orthopoxvirus infections released by SIGA Therapeutics
  • 08 Aug 2016 SIGA Technologies announces intention to submit NDA to US FDA in 2017
  • 17 Mar 2016 SIGA Technologies and Biomedical Advanced Research and Development Authority (BARDA) agree to co-develop tecovirimat IV formulation in USA for Orthopoxvirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top